

**Oklahoma Health Care Authority  
Drug Utilization Review Board  
(DUR Board)**

**Meeting – January 8, 2014 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

**1. Call To Order**

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

**2. Public Comment Forum**

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Shawna Kittridge, RPH, MHS:

**3. Independent Review of the SoonerCare Pharmacy Benefit and Management**

Items to be presented by Dr. Muchmore, Chairman:

**4. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**

- A. December 11, 2013 DUR Minutes – Vote
- B. December 11, 2013 DUR Recommendation Memorandum

Items to be presented by Dr. Le & Dr. Holderread, Dr. Muchmore, Chairman:

**5. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**

- A. Medication Coverage Activity for December 2013
- B. Pharmacy Help Desk Activity for December 2013

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Breo™ Ellipta™ (Fluticasone Furoate and Vilanterol Inhalation Powder) – See Appendix C.**

- A. COP Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

**7. 30 Day Notice to Prior Authorize Procsybi™ (Cysteamine Bitartrate) – See Appendix D.**

- A. Introduction
- B. Medication Summary
- C. COP Recommendations
- D. Product Details

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

**8. 30 Day Notice to Prior Authorize Ravicti® (Glycerol Phenylbutyrate) – See Appendix E.**

- A. Introduction
- B. Medication Summary
- C. COP Recommendations

D. Product Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

- 9. 30 Day Notice to Prior Authorize Sirturo™ (Bedaquiline Fumarate) – See Appendix F.**
- A. Introduction
  - B. Medication Summary
  - C. COP Recommendations
  - D. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 8. 30 Day Notice to Prior Authorize Tobi® (Tobramycin Solution), Tobi® Podhaler™ (Tobramycin Powder), and Pulmozyme® (Dornase Alfa) – Appendix G.**
- A. Introduction
  - B. Utilization Review
  - C. Utilization Details
  - D. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

- 9. FDA and DEA Updates – See Appendix H.**
- 10. Future Business**
- A. Annual Reviews
  - B. New Product Reviews
- 11. Adjournment**